Sun Pharma Acquisition: Sun Pharma to acquire US-based Organon in $11.75 billion deal, among biggest overseas buys by Indian firms Sun Pharmaceutical Industries announced on Monday that it will acquire US-based Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest overseas acquisitions by an Indian company. The transaction, approved by the boards of both firms, involves Sun Pharma purchasing all outstanding shares of Organon at $14 per share. The deal is expected to close in early 2027, contingent on regulatory clearances and shareholder approval. Following the announcement, Sun Pharma’s shares surged over 7%, rising 7.53% to Rs 1,742 on the BSE and 7.50% to Rs 1,742 on the NSE. The stock rally added Rs 27,462.59 crore to the company’s market valuation, pushing it to Rs 16,142.85 crore in morning trade. The acquisition is positioned as a strategic move to expand Sun Pharma’s global footprint and diversify its portfolio. Organon, a global healthcare firm spun off from Merck & Co. in 2021, operates six manufacturing facilities across the European Union and emerging markets. Its portfolio includes over 70 products spanning women’s health, biosimilars, and general medicines, sold in 140 countries. Post-acquisition, Sun Pharma is projected to enter the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. The company also aims to become a top-three player in global women’s health and the seventh-largest biosimilar company worldwide. Sun Pharma’s executive chairman, Dilip Shanghvi, emphasized the deal’s significance, stating it represents a “significant opportunity” due to Organon’s complementary portfolio and global reach.#sun_pharma #organon_co #dilip_shanghvi #carrie_cox #merck_co
Sun Pharma signs Definitive Agreement to Acquire Organon Sun Pharmaceutical Industries Limited and Organon & Co. have finalized a deal under which Sun Pharma will acquire all outstanding shares of Organon for US$14.00 per share in an all-cash transaction. The enterprise value of the deal is set at US$11.75 billion, marking a significant expansion for both companies. The acquisition, expected to close in early 2027, is subject to regulatory approvals and Organon stockholder approval. Organon, a global healthcare company spun off from Merck in 2021, specializes in women’s health and general medicines, with a portfolio of over 70 products. Its operations span 140 countries, including major markets such as the U.S., Europe, China, Canada, and Brazil. The company maintains six manufacturing facilities across the European Union and emerging markets, supporting its global footprint. Organon’s revenue for the year ended December 31, 2025, totaled US$6.2 billion, with Adjusted EBITDA of US$1.9 billion. It also reported debt of US$8.6 billion and a cash balance of US$574 million, bolstered by a recent divestiture that generated US$440 million in upfront payments. The acquisition aligns with Sun Pharma’s strategy to strengthen its Innovative Medicines business and expand its presence in biosimilars. The combined entity will become a top-25 global pharmaceutical company with projected revenue of US$12.4 billion, positioning it as a leader in Established Brands/Branded Generics and a top-3 player in women’s health. Sun Pharma’s entry into biosimilars as a Top-10 global player is a key outcome, leveraging Organon’s expertise and market reach. The deal also aims to enhance long-term value creation through synergies, including revenue upside opportunities and improved cash flow.#sun_pharma #merck #organon_co #organon #sun_pharmaceutical_industries_limited
Sun Pharma Acquires U.S. Firm Organon in $11.75 Billion Deal Sun Pharmaceutical Industries, India’s largest drugmaker, announced a major acquisition of New Jersey-based Organon & Co in an all-cash deal valued at $11.75 billion, including debt. The transaction involves purchasing all outstanding shares of Organon for $14.00 per share, significantly boosting Sun Pharma’s revenue to $12.4 billion. This places the company among the top 25 global pharmaceutical firms, according to the joint statement from both entities. Organon, which was spun off from Merck in 2021, specializes in women’s health and biosimilars. The U.S.-based company operates in over 140 countries and has more than 70 products in its portfolio. The acquisition is part of Sun Pharma’s strategy to expand its innovative medicines business, which currently covers dermatology, ophthalmology, and onco-dermatology. With the deal, the Indian company aims to increase its innovative medicines segment’s contribution to total sales from 20% to 27% by the financial year ending March 2025. The deal’s financial implications are notable. Organon carries a net debt-to-EBITDA ratio of 4 times, while Sun Pharma is described as “net positive.” Post-acquisition, the combined entity’s net debt-to-EBITDA ratio will drop to 2.3 times. Organon’s debt stood at $8.6 billion as of December 2025, with a cash balance of $574 million. Sun Pharma’s executive chairman, Dilip Shanghvi, highlighted the strategic value of the acquisition, stating that Organon’s portfolio and global reach complement Sun Pharma’s existing operations. The U.S. market, a key focus for Sun Pharma, will benefit from Organon’s presence, which includes sales in the U.S., Europe, China, Canada, and Brazil. Organon’s six manufacturing facilities span the European Union and emerging markets.#merck #sun_pharmaceutical_industries #organon_co #dilip_shanghvi #taro_pharma
